MASSY, FRANCE--(Marketwire - October 18, 2012) - Quantum Genomics (NYSE Euronext Paris: MLQGC) announces today the successful
completion of the first-in-human phase I clinical study with its product
QGC001.
QGC001 is the first of a new class of drugs that aim to treat high
blood
pressure through an inhibition of the aminopeptidase A enzyme (APA) at the
brain
level.

Lionel Segard, CEO of Quantum Genomics says: « The results of
this first
clinical study are very encouraging. All doses tested have been
well-tolerated.
A multiple ascending dose phase Ib study is underway and if successful,
we aim
to start phase II studies in hypertensive patients next year ».

About QGC001 and arterial hypertension

QGC001 is the first molecule of a new class of anti-hypertensive agents,
brain
aminopeptidase A inhibitors (BAPAI), which were co-discovered by the
research
teams of Dr. C. Llorens-Cortes (INSERM U1050/Collège de France) and
Prof. BP.
Roques (INSERM U1022/CNRS/Université Paris Descartes).

QGC001 could offer a therapeutic alternative for the treatment of high
blood
pressure for patients with Low Renin High Vasopressin profile (LRHV) whose
high
blood pressure is often more difficult to control with conventional
blockers of
the renin angiotensin system.

Arterial hypertension affects an estimated 1 billion people
worldwide (13
million people in France). Despite the availability of many
antihypertensive
drugs, 60% of patients diagnosed with hypertension are still poorly
controlled
by current medications for various reasons. Moreover, the overall
incidence of
resistant hypertension to at least three antihypertensive drugs
(including a
diuretic) is estimatedto be 10% of the hypertensive population.

The world market for anti-hypertensive drugs is projected to exceed
$66.2
billion by the year 2015. [1]

About Quantum Genomics

QGC is a biotechnology company developing new therapies in areas where an
unmet
medical need exists.

QGC is presently focused on the treatment of cardiovascular
diseases and
especially arterial hypertension.

The company is co-developing its products with academic teams and will
set up
strategic alliances and commercial partnerships with larger company in
order to
bring them to market.

The company is headquartered in Massy (France) under the leadership of
Lionel
Segard, supported by a management team of experienced people, including
Fabrice
Balavoine (VP Research & Development) and Michel Lepers (VP
Business
Development).

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.